Stifel analyst Paul Matteis raised the firm’s price target on KalVista (KALV) to $42 from $39 and keeps a Buy rating on the shares. Rapid growth in Ekterly starts “continues to disprove the bear case,” says the analyst, who is “encouraged” that the majority of revenue in Q4 was coming from refills versus new starts, calling this “a sign of sustainable growth.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista reports 8M EPS ($2.03) vs. ($2.30) last year
- KalVista sees cash runway through profitability
- Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
- KalVista announces new data from sebetralstat clinical trial program
- KalVista announces inclusion of Ekterly on Hereditary Angioedema guideline